Hanny Al-Samkari, MD, is the Peggy S. Blitz Endowed Chair in hematology and oncology at the Massachusetts General Hospital and an associate professor of medicine at Harvard Medical School.

Ianalumab Improves Stable Response, Reduces Fatigue in ITP, With Hanny Al-Samkari, MD

When combined with eltrombopag, ianalumab prolonged time to treatment failure (TTF), improved stable response at 6 months (SR6), reduced fatigue, facilitated tapering off eltrombopag, and delayed need for subsequent therapy in patients with 

 who had previously received corticosteroids, according to the VAYHIT2 trial.

ITP is an extremely common disorder, typically manifesting as bleeding. Its pathogenesis is highly complicated. ITP is caused by antibodies reacting to glycoproteins expressed on platelets and megakaryocytes, causing shortened survival of circulating platelets and impairing further production. Diminished numbers of regulatory T cells also contribute to its pathogenesis. While corticosteroids are the most common first-line therapy for ITP, they do not lead to durable remissions in most adults with ITP.

 American Society of Hematology (ASH) Annual Meeting and Exposition

 in Orlando, Florida, by Hammy Al-Samkari, MD, the Peggy S. Blitz Endowed Chair in hematology and oncology at the Massachusetts General Hospital and associate professor of medicine at Harvard Medical School, these data mark the second of 3 phase 3 studies in the VAYHIT program, evaluating the efficacy and safety of ianalumab.

“This is a very potent agent, a BAFF receptor inhibitor, that has a dual mechanism of action – it very potently depletes B cells and prevents the maturation and differentiation of new B cells,” Al-Samkari told 

 in an exclusive interview. “This is of significant potential in a disease driven by autoreactive B cells, particularly when given early in the course of the disease.”

VAYHIT2 was a randomized, double-blind, placebo-controlled phase 3 study. It included patients who had insufficient response to or relapse after first-line corticosteroid therapy (+/0 intravenous immunoglobulin), a platelet count <30x10

/L, and were naïve to and had an indication for second-line ITP treatment. Patients were randomly assigned in a 1:1:1 ratio to eltrombopag plus either ianalumab 9 mg/kg or 3 mg/kg, or placebo. Ianalumab and placebo were delivered as 4 once-monthly intravitreal infusions with eltrombopag for 16 weeks, followed by an 8-week eltrombopag tapering period.

The study’s primary endpoint was TTF, which was defined as time from randomization until platelet count reached <30x10

/L or start of rescue therapy 8 weeks after randomization, start of a new ITP therapy, inability to taper or discontinue eltrombopag by week 24, or death. The key secondary endpoint was SR6, defined as having ≥75% of platelet counts between weeks 19 and 25 being ≥50x10

Ultimately, 152 patients were enrolled in the trial – 50 were assigned to ianalumab 9 mg/kg, 51 to ianalumab 3 mg/kg, and 51 to placebo. The median follow-up period was 12.9 (interquartile range [IQR], 8.6-18), 13.6 (8.4-18.1), and 11.6 (8.1-18.2) months in the 9 mg/kg, 3 mg/kg, and placebo arms, respectively. TTF was substantially longer with ianalumab 9 mg/kg (HR 0.55; 95% CI, 0.32-0.92; log-rank 

 = .021) and ianalumab 3 mg/kg (HR, 0.58; 95% CI, 0.34-0.98; log-rank 

Additionally, substantially more patients achieved SR6 with ianalumab 9 mg/kg (n = 31) versus placebo (n = 20). At the end of the eltrombopag tapering period, fatigue reduction was -7.7 for ianalumab 9 mg/kg and -3.6 for placebo. All grade adverse events were also similar between arms, with grade ≥3 events occurring in 12, 10, and 2 patients in the 9 mg/kg, 3 mg/kg, and placebo arms, respectively. Grade ≥3 neutropenia occurred in 5 and 2 patients in the 9 mg/kg and 3 mg/kg arms, respectively, and no on-treatment events led to ianalumab discontinuations.

Ultimately, Al-Samkari and colleagues determined that ianalumab, when combined with eltrombopag, efficaciously reduces fatigue, facilitates tapering off eltrombopag, prolonged TTF, improved SR6, and delayed the need for subsequent therapy. It was well tolerated with no observed increase in infection risk versus placebo.

“The remaining question, which we will answer with long-term follow-up, is whether ianalumab will be disease-modifying in addition to providing a long duration of treatment-free response,” Al-Samkari said. “Will it allow patients who would have otherwise progressed to a more severe chronic course to have a milder course? That’s something we’re still looking to answer.”

Editor’s Note: Al-Samkari reports disclosures with Pharmacosmos, Agios, Amgen, Vaderis, Novartis, Sobi, and others.

Al-Samkari H, Cuker A, Zaja F, et al. Primary results from VAYHIT2, a randomized, double-blind, phase 3 trial of ianalumab plus eltrombopag versus placebo plus eltrombopag in patients with primary immune thrombocytopenia (ITP) who failed first-line corticosteroid treatment. Abstract presented at the 67

 American Society of Hematology Annual Meeting. Orlando, FL. December 6-9, 2025.

Kistangari G, McCrae KR. Immune thrombocytopenia. Hematol Oncol Clin North Am. 2013;27(3):495-520. 

Videos

Al-Samkari discusses the positive results from the VAYHIT2 trial, which investigated ianalumab in combination with eltrombopag in adults with ITP.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Hematology

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Chelsie Derman is an associate editor for 

who covers psychiatry, sleep medicine, geriatrics, migraine, and allergy. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

Teva Pharmaceuticals announced on December 9, 2025, that the company submitted a New Drug Application (NDA) to the 

 for olanzapine extended-release injectable suspension (TEV-‘749) for the treatment of

“The innovation of olanzapine LAI comes from its delivery of olanzapine, a foundational treatment for schizophrenia, as a once-monthly subcutaneous formulation,” said Eric Hughes, MD, PhD, executive vice president, global R&D and chief medical officer at Teva, in a statement.

The NDA submission includes results from the phase 3, multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled 56-week SOLARIS trial assessing the efficacy, safety, and tolerability of TEV-749, a second-generation antipsychotic olanzapine, in patients aged 18 – 64 years with schizophrenia. TEV- ‘749 uses SteadyTeq™, a copolymer technology proprietary to Medincell that delivers a controlled steady, sustained release of olanzapine.

In the first 8 weeks, 675 patients were randomized 1:1:1 to receive once-monthly TEV-‘749 at a low, medium, or high dose, or placebo. For the next 48 weeks, patients who completed the first period were randomized and equally allocated to 1 of the 3 olanzapine arms. The end-of-treatment visit took place 4 weeks after the administration of the last treatment dose, followed by a follow-up visit 4 weeks after.

The trial demonstrated a consistent efficacy and safety profile compared to currently available oral olanzapine formulations. In April, Teva shared that 92% of 70 patients, 87% of 24 nurses, and 73% of 11 physicians reported high satisfaction with TEV-‘749. Unlike other long-acting injectables, which consist of 2 basic molecules—risperidone and aripiprazole—TEV’749 offers a new molecule.

“Not every patient responds well or tolerates all medicines,” SOLARIS investigator Andrew J. Cutler, MD, clinical associate professor of psychiatry at SUNY Upstate Medical University, told 

 “It's nice to have another option that some people may do especially well with.”

Approximately 1% of the world’s population and 3.5 million individuals in the US will develop schizophrenia in their lifetime, with approximately 80% of patients experiencing multiple relapses over the first 5 years of treatment.

 Each relapse raises the risk of loss of function, treatment refractoriness, and changes in brain morphology. TEV- ‘749 may have the potential to support real-world adherence and improve stability, addressing the treatment gap for people living with schizophrenia.

“Teva is committed to working closely with the FDA on the review of this olanzapine LAI application as we seek to help address the critical unmet needs of people living with schizophrenia,” Hughes continued.

Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension. Tevapharm.com. Published December 9, 2025. Accessed December 9, 2025. https://www.tevapharm.com/news-and-media/latest-news/teva-pharmaceuticals-submits-new-drug-application-to-fda-for-olanzapine-extended-release-injectable-suspe/

Cutler A. TEV- ‘749 Once-Monthly LAI Yields High Satisfaction in Phase 3 Trial, with Andrew J. Cutler, MD. HCPLive. April 21, 2025. 

https://www.hcplive.com/view/tev--749-once-monthly-lai-yields-high-satisfaction-in-phase-3-trial-with-andrew-j-cutler-md

Articles

Teva Pharmaceuticals has submitted a New Drug Application to the FDA for olanzapine extended-release injectable suspension (TEV-‘749) for adult schizophrenia treatment. This once-monthly subcutaneous formulation utilizes SteadyTeq™, a proprietary copolymer technology, ensuring a controlled release. The submission includes data from the 56-week SOLARIS trial, which demonstrated consistent efficacy and safety compared to oral olanzapine. High satisfaction rates were reported among patients, nurses, and physicians. TEV-‘749 offers a novel molecule, potentially improving adherence and addressing treatment gaps in schizophrenia management.

Teva submitted an NDA on olanzapine extended-release injectable suspension (TEV-‘749) for adult schizophrenia to the FDA.

FDA News

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Schizophrenia

The HCPLive schizophrenia page is a resource for medical news and expert insights on the mental disorder. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for schizophrenia, and more.

Teva Pharmaceuticals Submits NDA on TEV-‘749 for Schizophrenia to the FDA

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

In patients with severe alcohol-associated hepatitis (sAH), corticosteroid therapy is independently associated with a significantly decreased risk of acute kidney injury (AKI) development, according to new research.

Findings from the post-hoc analysis of VTL-308, a phase 3, randomized, open-label, multicenter study evaluating patients with alcohol-induced liver decompensation or severe alcohol-associated hepatitis, suggest a protective effect against AKI but no impact on recovery once AKI has occurred.

“Our findings suggest that early corticosteroid therapy may reduce the risk of AKI, highlighting a potential renoprotective effect beyond its known impact on liver inflammation, ” wrote study investigator Laura Buttler from the department of gastroenterology at Hannover Medical School, and colleagues.

The study included 151 patients with sAH, diagnosed based on alcohol use ≤6 weeks before admission, consistent with alcohol-induced liver decompensation and by fulfilling either histological confirmation or ≥ 2 typical clinical features alongside a bilirubin ≥ 16 mg/dl and a Maddrey discriminant function (DF) score ≥ 3.To identify factors independently associated with the development of AKI, investigators analyzed 140 patients without AKI at baseline.

Investigators analyzed 63 cases of AKI, classifying incidence, clinical relevance, and associated risk factors. The diagnosis of AKI was based on an acute increase of serum creatinine (sCr) ≥ 0.3 mg/dl (≥ 26.5 μmol/l) from baseline within 48 h, or a ≥ 50% increase in sCr from a known value within the prior seven days.

Upon a competing risk analysis, investigators noted a significant association between AKI and increased mortality within 90 days. In the univariate analysis, AKI was associated with a subdistribution hazard ratio (sHR) of 9.23 (95% Confidence Interval [CI], 3.63–23.50; 

 < .001). This association remained robust in the multivariate model after adjustment for GAHS (sHR, 8.74; 95% CI, 3.43–22.26; 

Cox regression analysis with time-dependent covariates confirmed the significant effect of AKI on mortality, showing an HR of 12.69 in the univariate analysis (95% CI, 4.92–32.72; 

 < .001) and an HR of 12.05 in the multivariate model (95% CI, 4.62–31.08; 

In a 90-day follow-up, corticosteroids were significantly associated with a reduced risk of developing AKI. Upon competing risk analysis, investigators saw a significantly decreased risk of AKI in patients with steroid therapy compared to those without (univariate sHR, 0.49; 95% CI, 0.28–0.88; 

This protective effect remained robust after adjusting for bilirubin levels in the multivariate model (sHR, 0.47; 95% CI: 0.27–0.84; 

 = 0.01) and after matching of patients with and without corticosteroid intake (sHR = 0.46; 95% CI, 0.25–0.85; 

 = 0.01). In Cox regression analysis, corticosteroid therapy was not significantly associated with AKI reversal (Hazard Ratio [HR], 1.15; 95% CI, 0.51–2.57; 

“Our study identified a consistent protective association between corticosteroid therapy and AKI, a finding with potential therapeutic implications in this vulnerable population,” investigators concluded. “Therefore, our study might contribute to the initiation of future prospective trials to further investigate the association between corticosteroids and AKI development.”

Buttler L, Stange J, Pyrsopoulos N, et al. Steroid therapy is linked to lower incidence of acute kidney injury in patients with severe alcohol-associated hepatitis. 

https://doi.org/10.1038/s41598-025-29912-4

Vital Therapies, Inc. Vital Therapies Announces That Topline Results of VTL-308 Fail to Achieve Primary and Secondary Endpoints of Improvement in Survival. GlobeNewswire News Room. Published September 12, 2018. Accessed December 8, 2025. 

https://www.globenewswire.com/news-release/2018/09/12/1569553/31568/en/Vital-Therapies-Announces-That-Topline-Results-of-VTL-308-Fail-to-Achieve-Primary-and-Secondary-Endpoints-of-Improvement-in-Survival.html

Corticosteroid therapy in patients with severe alcohol-associated hepatitis (sAH) is linked to a reduced risk of developing acute kidney injury (AKI), though it does not aid in AKI recovery. A post-hoc analysis of the VTL-308 study, involving 151 patients, revealed a significant association between AKI and increased 90-day mortality. Corticosteroids showed a protective effect against AKI, with a decreased risk observed in both univariate and multivariate analyses. These findings suggest potential therapeutic implications and warrant further prospective trials to explore corticosteroids' role in AKI prevention.

VTL-308 post-hoc analysis shows corticosteroids may decrease AKI risk in severe alcohol-associated hepatitis, but don’t affect recovery. 


Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Steroids Linked to Reduced Risk of Acute Kidney Injury in Severe Alcohol-Associated Hepatitis

Tim Smith joined the MJH Life Sciences team as an assistant editor for HCPLive in August 2022. He graduated from UC Berkeley with a degree in political science, working in multimedia journalism as a staff writer prior to joining MJH. In his spare time, he enjoys reading, watching TV, listening to podcasts, and rock climbing. You can contact him at 

Several monoclonal antibodies significantly outperformed placebo for key 

 endpoints, new systematic review data suggest, with dupilumab having the strongest overall efficacy and safety profile.

These data also suggest spesolimab and rademikibart led individual Eczema Area and Severity Index (EASI) score response rankings. The findings resulted from a systematic review and meta-analysis authored by investigators such as Jinping Zhang, MD, of Nanjing Drum Tower Hospital.

Zhang et al noted set out to compare safety and efficacy findings on monoclonal antibodies for the treatment of moderate-to-severe atopic dermatitis. They highlighted the growing necessity of evaluating monoclonal antibodies relative impacts, noting the consequent value of network meta-analyses (NMA).

“This systematic review and NMA aim to comprehensively assess all mAb used in moderate-to-severe AD, ranking their therapeutic and safety profiles to inform clinical decision-making,” Zhang and coauthors wrote.

From the time of database inception to November 2024, the investigative team carried out a comprehensive search of the Embase, PubMed, Web of Science, and Cochrane Library databases. They incorporated the terms 

 “Amlitelimab,” “Astegolimab,” “CM310,” “Dupilumab,” “Eblasakimab,” “Fezakinumab,” 

 “Lebrikizumab,” “Rademikibart,” “Spesolimab,” “Tralokinumab,” “Ustekinumab,” and “Randomized controlled trial" into their searches.

References identified within the records the team assessed were also reviewed by Zhang and colleagues to ensure that no relevant research was overlooked. Randomized controlled trials which were published in English were deemed eligible. Participants included within their assessment had been given monoclonal antibody monotherapy, and any research combining such drugs with corticosteroids were not included.

Placebo served as the comparator across the various trials included in Zhang et al's analysis. Additionally, the investigators did not include studies without detailed information on EASI-50, EASI-75, or EASI-90, or those without a placebo arm, in their consideration. The main endpoints evaluated by the team consisted of EASI-50, EASI-75, EASI-90, and the proportion of included subjects attaining an Investigator’s Global Assessment (IGA) score of 0 or 1.

Among the secondary outcomes evaluated, Zhang et al highlighted percentage changes from the point of baseline in EASI, Pruritus Numerical Rating Scale (NRS), and SCORing Atopic Dermatitis (SCORAD), as well as any shifts in Body Surface Area (BSA) and Dermatology Life Quality Index (DLQI). Safety assessments were focused on any occurrences of adverse events (AEs), serious AEs, and treatment cessation resulting from AEs.

NoteExpress software was implemented by Zhang and colleagues to manage and organize the available research. They had 2 reviewers to carry out the initial screening of all data and align their selection criteria. A third reviewer looked into any articles for which disagreements arose. Data extraction was performed by the investigative team utilizing Excel 2019, with a single researcher entering data and another conducting verification.

There were 607 records assessed by the team, and 253 duplicates were removed. This left 354 unique articles. The screening of titles and abstracts excluded 242 of these studies, and another 80 articles were taken out by the investigators following the performance of their full-text evaluations. The final dataset consisted of 32 eligible studies.

Altogether, there were 32 RCTs involving 7588 subjects were included. Spesolimab, dupilumab, rademikibart, and amlitelimab all showed superior performance compared with placebo for EASI-50 (risk ratios 1.31–22.65), EASI-75 (1.51–36.58), EASI-90 (3.72–5.49), and attaining an IGA score of 0 or 1 (1.78–13.36). Basing their conclusions on SUCRA rankings, Zhang and colleagues found dupilumab performed particularly well across percent reductions in EASI, NRS, and SCORAD.

Overall, treatment with dupilumab was shown by the investigative team to have a significantly lower incidence of serious AEs compared to placebo (RR = 0.43, 95% CI 0.30–0.63). Other safety analyses identified by Zhang and coauthors demonstrated no statistically significant distinctions between treatment and control cohorts in these studies.

“NMA provided effective evidence for evaluating the efficacy and safety of monoclonal antibody in the treatment of AD,” they wrote.

 “From the perspective of SUCRA ranking, Spesolimab may be the best option to improve EASI-50. Rademikibart may be considered more effective than other interventions in improving EASI-75, while Dupilumab may be most beneficial for EASI-90. Dupilumab had better efficacy in improving NRS, EASI and SCORAD scores.”

W Cai, L Fu, J Zhang. Efficacy and Safety of All Monoclonal Antibodies in Moderate-to-Severe Atopic Dermatitis: A Systematic Review and Network Meta-Analysis. Pharmacoepidemiology and Drug Safety 34, no. 12 (2025): e70268, 

S Lin, Q Shi, F Yang, et al. Traditional Chinese Medicine Injections for Heart Failure: A Protocol for Systematic Review and Network Meta-Analysis of Randomised Controlled Trials. BMJ Open 10, no. 9 (2020): e37331.

A systematic review and meta-analysis evaluated the efficacy and safety of monoclonal antibodies for moderate-to-severe atopic dermatitis. Dupilumab demonstrated the strongest overall efficacy and safety profile, outperforming placebo in key endpoints such as EASI-50, EASI-75, and EASI-90. Spesolimab and rademikibart also showed significant efficacy in specific EASI score responses. The study included 32 randomized controlled trials with 7588 subjects, highlighting the importance of network meta-analyses in assessing monoclonal antibodies' relative impacts. Dupilumab was associated with a lower incidence of serious adverse events compared to placebo.

This study aimed to compare the efficacy and safety of monoclonal antibodies (mAb) for moderate-to-severe atopic dermatitis.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Dupilumab Superior in Analysis of Monoclonal Antibodies for Atopic Dermatitis

Sayna Norouzi, MD, is an assistant professor of medicine, clinical nephrologist, and founder and director of the glomerular disease and polycystic kidney disease clinics at Loma Linda University Medical Center.

Chee Kay Cheung MBChB PhD, is a consultant nephrologist and honorary senior lecturer at the University of Leicester.

Current Disease-Modifying Treatment Options in IgAN

In this segment, the panel discusses how the treatment landscape for IgA nephropathy is evolving with the introduction of disease-targeted therapies. They highlight targeted-release budesonide, formulated to act in the gut-associated lymphoid tissue, where galactose-deficient IgA1 is produced. This allows reduction of pathogenic IgA at its source while avoiding the broader immunosuppression seen with systemic steroids. The discussion also includes sparsentan, a dual endothelin receptor antagonist and angiotensin receptor blocker, which has shown meaningful reductions in proteinuria compared with standard RAAS blockade alone. These agents are contrasted with SGLT2 inhibitors, which remain part of optimized supportive care but do not directly address the underlying immune mechanism. The panel notes that while these therapies represent important progress, access and reimbursement may limit uptake in real-world settings. Still, they agree that these additions mark a shift toward disease-modifying treatment strategies rather than relying solely on supportive care.

In this segment, the panel discusses how the treatment landscape for IgA nephropathy is evolving with the introduction of disease-targeted therapies.

Video Series

Healthcare professionals discuss strategies for effectively lowering LDL cholesterol in patients post-cardiac events, emphasizing early intervention and tailored therapies.

Optimizing the Timing of PCSK9 Therapy After an ASCVD Event

The panel examines drug classes targeting the BAFF and APRIL pathways, which play key roles in the production and regulation of IgA-secreting plasma cells.

Exploring the Therapeutic Potential of B-Cell Modulation in IgAN

Princess Ogbogu, MD, from the University of Hospitals Rainbow Babies & Children’s Hospital

This HCPLive Five features advancements in asthma, immunology, and allergy that were presented at the ACAAI 2025 meeting in Orlando.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

HCPLive Five at ACAAI 2025

Healthcare professionals explore effective strategies for LDL cholesterol management, emphasizing patient involvement and innovative therapies for optimal outcomes.

Identifying Candidates for PCSK9 Therapy After ASCVD Events

Viet Le, DMSc, PA-C, is a preventive cardiology PA at Intermountain Health and the former president of the Academy of Physician Associates in Cardiology.

GLP-1 receptor agonists revolutionize treatment in cardiology, offering new hope for heart failure and related conditions beyond weight loss.

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Atherosclerotic Cardiovascular Disease

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

This Year In Medicine

Beyond Weight Loss: How GLP-1 RAs Established a Role in Cardiology in 2025

Investigators evaluated current prescription patterns for systemic HS medications among European HS specialists and opinions on criteria for biologic upgrades.

Hidradenitis Suppurativa

Hidradenitis Suppurativa condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatology research, treatment, and drug development.

HS Specialists Express Support for Earlier Use of Biologics Among Patients

Ibrahim Gwarzo, MPH, MBBS, DrPH, is a research scientist at Nemours Children's Health.

Gwarzo discussed the shortcomings faced by many patients with SCD during pain crises, due to less frequent opioid prescription than guidelines recommend.

Opioid Prescription for Sickle Cell Disease Misses Guideline Recommendation, With Ibrahim Gwarzo, MPH

In women with CKD, there are no general survival advantages compared to the male patient population. 


Chronic Kidney Disease

Women's Health

On the HCPLive women's health page, resources on the topics of medical news and expert insight into obstetrics, gynecology, and women's related health can be found. Content includes articles, interviews, videos, podcasts, and breaking news on women's health, and more.

Stage 5 CKD May Reverse Female Survival Advantage

Following its 2025 FDA approval, lumateperone 42 mg demonstrated meaningful reductions in MADRS and CGI-S scores in adults with major depressive disorder.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

Adjunctive Lumateperone Significantly Improves MDD Symptoms by Day 43 

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

Announced by Cogent Biosciences, these data indicate bezuclastinib’s capacity for improving patient-reported symptoms of mast cell burden.

Latest News

Ianalumab Improves Stable Response, Reduces Fatigue in ITP, With Hanny Al-Samkari, MD

Teva Pharmaceuticals Submits NDA on TEV-‘749 for Schizophrenia to the FDA

Steroids Linked to Reduced Risk of Acute Kidney Injury in Severe Alcohol-Associated Hepatitis

Dupilumab Superior in Analysis of Monoclonal Antibodies for Atopic Dermatitis

Current Disease-Modifying Treatment Options in IgAN